Susann Busch
YOU?
Author Swipe
View article: Supplementary Table S4 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Table S4 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Gene list of customized RT² Profiler PCR Array (SABiosciences).
View article: Supplementary Figure S2 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S2 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
SMAD2 phosphorylation (pSMAD2) and its associations to survival outcome in invasive breast cancer.
View article: Supplementary Figure S2 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S2 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
SMAD2 phosphorylation (pSMAD2) and its associations to survival outcome in invasive breast cancer.
View article: Supplementary Figure S8 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S8 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Survival outcome according to ERα status in invasive breast cancer.
View article: Supplementary Figure S1 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S1 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Flow chart of SBII2 cohort study design regarding analysis of TGFBR2 and pSMAD2 biomarker.
View article: Supplementary Figure S7 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S7 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Transcriptional activity and TGFBR2 overexpression in MCF7 and tamoxifen-resistant cells (TAM-R).
View article: Supplementary Figure S5 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S5 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
TGFβ and ERα transcriptional activity.
View article: Supplementary Figure S4 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S4 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Pharmacological inhibition of TGFβ signaling.
View article: Supplementary Table S4 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Table S4 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Gene list of customized RT² Profiler PCR Array (SABiosciences).
View article: Supplementary Table S2 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Table S2 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Correlations of SMAD2 phosphorylation to clinico-pathological parameters and molecular markers.
View article: Supplementary Figure S3 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S3 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Viability of MCF7 with TGFBR2-specific knockdown.
View article: Supplementary Figure S3 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S3 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Viability of MCF7 with TGFBR2-specific knockdown.
View article: Supplementary Figure S8 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S8 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Survival outcome according to ERα status in invasive breast cancer.
View article: Supplementary Figure S6 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S6 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Fulvestrant response in MCF7 with TGFBR2-specific knockdown.
View article: Supplementary Table S3 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Table S3 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Multivariate analysis of recurrence-free survival regarding prognostic information of SMAD2 phosphorylation.
View article: Supplementary Table S1 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Table S1 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Multivariate analysis of recurrence-free survival regarding prognostic information of TGFBR2.
View article: Data from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Data from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
One third of the patients with estrogen receptor α (ERα)-positive breast cancer who are treated with the antiestrogen tamoxifen will either not respond to initial therapy or will develop drug resistance. Endocrine response involves crossta…
View article: Supplementary Table S2 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Table S2 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Correlations of SMAD2 phosphorylation to clinico-pathological parameters and molecular markers.
View article: Supplementary Figure S1 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S1 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Flow chart of SBII2 cohort study design regarding analysis of TGFBR2 and pSMAD2 biomarker.
View article: Supplementary Table S1 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Table S1 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Multivariate analysis of recurrence-free survival regarding prognostic information of TGFBR2.
View article: Supplementary Figure S7 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S7 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Transcriptional activity and TGFBR2 overexpression in MCF7 and tamoxifen-resistant cells (TAM-R).
View article: Supplementary Figure S4 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S4 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Pharmacological inhibition of TGFβ signaling.
View article: Data from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Data from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
One third of the patients with estrogen receptor α (ERα)-positive breast cancer who are treated with the antiestrogen tamoxifen will either not respond to initial therapy or will develop drug resistance. Endocrine response involves crossta…
View article: Supplementary Table S3 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Table S3 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Multivariate analysis of recurrence-free survival regarding prognostic information of SMAD2 phosphorylation.
View article: Supplementary Figure S6 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S6 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
Fulvestrant response in MCF7 with TGFBR2-specific knockdown.
View article: Supplementary Figure S5 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance
Supplementary Figure S5 from Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance Open
TGFβ and ERα transcriptional activity.
View article: Cellular organization and molecular differentiation model of breast cancer-associated fibroblasts
Cellular organization and molecular differentiation model of breast cancer-associated fibroblasts Open
Within this comprehensive study we have identified distinct and intersecting molecular profiles defining fibroblast activation states and propose that underlying cellular heterogeneity, fibroblasts are hierarchically organized. Understandi…
View article: CAF-specific markers: role of the TGFβ pathway
CAF-specific markers: role of the TGFβ pathway Open
The predominantly tumorigenic actions of transforming growth factor-beta (TGFβ) in aggressive cancer make the TGFβ pathway an attractive target for therapeutic intervention. Currently a number of TGFβ-targeted cancer therapies are in clini…